Skip to main content
Erschienen in:

01.03.2015 | Leitthema

Adjuvante und neoadjuvante Chemotherapie des Mammakarzinoms

verfasst von: M. Untch, Prof. Dr. C. Thomssen

Erschienen in: Die Onkologie | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Dank adjuvanter Therapien hat sich die Prognose des frühen Mammakarzinoms entscheidend verbessert. Bei lokal fortgeschrittenen, primär inoperablen oder inflammatorischen Mammakarzinomen sowie bei primär operablen Hochrisikotumoren wird heute meist eine neoadjuvante sytemische Therapie angewandt.

Ziel

Darstellung der optimalen (neo)adjuvanten Therapie für einzelne Patientinnensubgruppen sowie aktueller Studienergebnisse.

Material und Methoden

Interpretation der derzeitigen Datenlage zur (neo)adjuvanten Therapie, Darstellung der Therapieempfehlungen und aktueller Studienkonzepte.

Ergebnisse

Adjuvante und neoadjuvante Chemotherapie mit Anthrazyklinen, Cyclophosphamid und Taxanen sind hinsichtlich des Überlebens gleichwertig. Es besteht eine Korrelation der pathologischen Komplettremission (pCR) nach neoadjuvanter Chemotherapie mit einem verlängerten Überleben v. a. bei Patientinnen mit hormonrezeptornegativen (Chemotherapie) und HER2-positiven Tumoren (Chemotherapie plus Trastuzumab).

Schlussfolgerung

Patientinnen ohne pCR haben eher eine ungünstige Prognose und bedürfen neuer postoperativer Therapien im Rahmen von Studien. Dosisdichte Chemotherapien spielen in der (neo)adjuvanten Therapie eine zunehmende Rolle. Patientinnen ohne pCR haben eher eine ungünstige Prognose und bedürfen neuer postoperativer Therapien im Rahmen von Studien.
Literatur
1.
Zurück zum Zitat Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG) (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444CrossRef Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG) (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444CrossRef
2.
Zurück zum Zitat AGO Breast Committee. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Recommendations 2014. http://www.ago-online.de, download 8.12.2014 AGO Breast Committee. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Recommendations 2014. http://​www.​ago-online.​de, download 8.12.2014
3.
Zurück zum Zitat NCCN Guidelines. (http://www.nccn.org; Version 2.2014; download 15.3. 2014) NCCN Guidelines. (http://​www.​nccn.​org; Version 2.2014; download 15.3. 2014)
4.
Zurück zum Zitat Schlitt A, Jordan K, Vordermark D et al (2014) Kardiotoxizität onkologischer Therapien. Dtsch Arztebl Int 111(10):161–168PubMedCentralPubMed Schlitt A, Jordan K, Vordermark D et al (2014) Kardiotoxizität onkologischer Therapien. Dtsch Arztebl Int 111(10):161–168PubMedCentralPubMed
5.
Zurück zum Zitat Jones S, Holmes FA, O’Shaughnessy J et al (2009) Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27(8):1177–1183CrossRefPubMed Jones S, Holmes FA, O’Shaughnessy J et al (2009) Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27(8):1177–1183CrossRefPubMed
6.
Zurück zum Zitat Slamon D, Eiermann W, Robert N et al (2011) Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283CrossRefPubMedCentralPubMed Slamon D, Eiermann W, Robert N et al (2011) Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431–1439CrossRefPubMed Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431–1439CrossRefPubMed
8.
Zurück zum Zitat Cognetti F, Bruzzi P, De Placido S et al (2013) Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the gruppo Italiano mammella (GIM)-2 randomized phase III study. Vortrag San Antonio Breast Cancer Symposium S5–06 Cognetti F, Bruzzi P, De Placido S et al (2013) Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the gruppo Italiano mammella (GIM)-2 randomized phase III study. Vortrag San Antonio Breast Cancer Symposium S5–06
9.
Zurück zum Zitat Moebus VJ, Jackisch C, Lueck HJ et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk breast cancer patients (≥ 4+ LN): Mature results of an AGO-phase-III study. J Clin Oncol 28(17):2874–2880CrossRefPubMed Moebus VJ, Jackisch C, Lueck HJ et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk breast cancer patients (≥ 4+ LN): Mature results of an AGO-phase-III study. J Clin Oncol 28(17):2874–2880CrossRefPubMed
10.
Zurück zum Zitat Budd GT, Barlow WE, Moore HCF et al (2013) S0221: comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. J Clin Oncol (suppl; abstr CRA1008) Budd GT, Barlow WE, Moore HCF et al (2013) S0221: comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. J Clin Oncol (suppl; abstr CRA1008)
11.
Zurück zum Zitat Sikov WM, Berry DA, Perou CM et al (2014) Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). J Clin Oncol. pii: JCO.2014.57.0572 Sikov WM, Berry DA, Perou CM et al (2014) Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). J Clin Oncol. pii: JCO.2014.57.0572
12.
Zurück zum Zitat Brito RA, Valero V, Buzdar AU et al (2001) Long-term results of combined modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 19:628–633PubMed Brito RA, Valero V, Buzdar AU et al (2001) Long-term results of combined modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 19:628–633PubMed
13.
Zurück zum Zitat Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493PubMed Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493PubMed
14.
Zurück zum Zitat Kaufmann M, Hortobagyi GN, Goldhirsch A et al (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24:1940–1949CrossRefPubMed Kaufmann M, Hortobagyi GN, Goldhirsch A et al (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24:1940–1949CrossRefPubMed
15.
Zurück zum Zitat Minckwitz G von, Untch M, Nuesch E et al (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125:145–156CrossRef Minckwitz G von, Untch M, Nuesch E et al (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125:145–156CrossRef
16.
Zurück zum Zitat Mamounas EP, Anderson SJ, Dignam JJ et al (2012) Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 30:3960–3966CrossRefPubMedCentralPubMed Mamounas EP, Anderson SJ, Dignam JJ et al (2012) Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 30:3960–3966CrossRefPubMedCentralPubMed
17.
Zurück zum Zitat Nes JG van, Putter H, Julien JP et al (2009) Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat 115(1):101–113CrossRefPubMed Nes JG van, Putter H, Julien JP et al (2009) Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat 115(1):101–113CrossRefPubMed
18.
Zurück zum Zitat U. S. Food and Drug Administration. Accelerated approval pertuzumab. Sep 30, 2013. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm370449.htm. Zugegriffen: 13. Dez. 2014 U. S. Food and Drug Administration. Accelerated approval pertuzumab. Sep 30, 2013. http://​www.​fda.​gov/​Drugs/​InformationOnDru​gs/​ApprovedDrugs/​ucm370449.​htm.​ Zugegriffen: 13. Dez. 2014
19.
Zurück zum Zitat Minckwitz G von, Blohmer J-U, Costa S-D et al (2011) Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients – result of the GeparTrio Trial. Cancer Res 24(Suppl 3):S3–S2 Minckwitz G von, Blohmer J-U, Costa S-D et al (2011) Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients – result of the GeparTrio Trial. Cancer Res 24(Suppl 3):S3–S2
20.
Zurück zum Zitat Loibl S, Minckwitz G von, Untch M et al (2011) pCR as a Surrogate in HER-2-positive patients treated with Trastuzumab. Cancer Res 24(Suppl 3):S5–S4 Loibl S, Minckwitz G von, Untch M et al (2011) pCR as a Surrogate in HER-2-positive patients treated with Trastuzumab. Cancer Res 24(Suppl 3):S5–S4
21.
Zurück zum Zitat Minckwitz G von, Untch M, Nuesch E et al (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125:145–156CrossRef Minckwitz G von, Untch M, Nuesch E et al (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125:145–156CrossRef
22.
Zurück zum Zitat Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377–384CrossRefPubMed Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377–384CrossRefPubMed
23.
Zurück zum Zitat Untch M, Fasching AP, Konecny EG et al (2011) Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy. Three year median follow up data of the TECHNO trial. J Clin Oncol 29:3351–3357CrossRefPubMed Untch M, Fasching AP, Konecny EG et al (2011) Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy. Three year median follow up data of the TECHNO trial. J Clin Oncol 29:3351–3357CrossRefPubMed
24.
Zurück zum Zitat Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 38:164–172CrossRef Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 38:164–172CrossRef
25.
Zurück zum Zitat Petrelli F., Barni S (2012) Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better. Med Oncol 29:503–510CrossRefPubMed Petrelli F., Barni S (2012) Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better. Med Oncol 29:503–510CrossRefPubMed
26.
Zurück zum Zitat Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32CrossRefPubMed Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32CrossRefPubMed
27.
Zurück zum Zitat Buzdar AU, Suman VJ, Meric-Bernstam F et al (2013) American College of Surgeons Oncology Group investigators. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol 14(13):1317–1325CrossRefPubMedCentralPubMed Buzdar AU, Suman VJ, Meric-Bernstam F et al (2013) American College of Surgeons Oncology Group investigators. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol 14(13):1317–1325CrossRefPubMedCentralPubMed
28.
Zurück zum Zitat Tolaney SM, Barry WT, Dang CT et al (2013) A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Vortrag San Antonio Breast Cancer Symposium S1–04 Tolaney SM, Barry WT, Dang CT et al (2013) A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Vortrag San Antonio Breast Cancer Symposium S1–04
29.
Zurück zum Zitat Slamon D, Eiermann W, Robert N et al (2011) Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283CrossRefPubMedCentralPubMed Slamon D, Eiermann W, Robert N et al (2011) Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283CrossRefPubMedCentralPubMed
30.
Zurück zum Zitat Jones SE, Collea R, Paul D et al (2013) Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol 14(11):1121–1128CrossRefPubMed Jones SE, Collea R, Paul D et al (2013) Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol 14(11):1121–1128CrossRefPubMed
31.
Zurück zum Zitat Minckwitz G von, Schneeweiss A, Loibl S et al (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15(7):747–756CrossRef Minckwitz G von, Schneeweiss A, Loibl S et al (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15(7):747–756CrossRef
32.
Zurück zum Zitat Hurley J, Reis IM, Rodgers SE et al (2013) The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat Hurley J, Reis IM, Rodgers SE et al (2013) The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat
33.
Zurück zum Zitat Cameron D, Brown J, Dent R et al (2013) Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 14(10):933–942CrossRefPubMed Cameron D, Brown J, Dent R et al (2013) Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 14(10):933–942CrossRefPubMed
Metadaten
Titel
Adjuvante und neoadjuvante Chemotherapie des Mammakarzinoms
verfasst von
M. Untch
Prof. Dr. C. Thomssen
Publikationsdatum
01.03.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Onkologie / Ausgabe 3/2015
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-014-2839-3

Weitere Artikel der Ausgabe 3/2015

Der Onkologe 3/2015 Zur Ausgabe

Einführung zum Thema

Paradigma Brustkrebs

CME Zertifizierte Fortbildung

Fehl- und Mangelernährung in der Onkologie

Journal Club

AMAROS-Studie

Neu im Fachgebiet Onkologie

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Weißer Hautkrebs: Ein Update zu Diagnostik und Therapie

18.07.2024 Fortbildungswoche 2024 Kongressbericht

In der aktualisierten Version der S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ gibt es neue Empfehlungen, unter anderem zu erweiterten Optionen bei aktinischer Keratose sowie zur systemischen und chirurgischen Behandlung von Plattenepithelkarzinomen. Ein Überblick.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.